Targeting the NG2/CSPG4 proteoglycan retards tumour growth and angiogenesis in preclinical models of GBM and melanoma.

by Jian Wang, Agnete Svendsen, Justyna Kmiecik, Heike Immervoll, Kai Ove Skaftnesmo, Jesús Planagumà, Rolf Kåre Reed, Rolf Bjerkvig, Hrvoje Miletic, Per Øyvind Enger, Cecilie Brekke Rygh, Martha Chekenya
Published 2011-01-01